US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Gilead Sciences
(NQ:
GILD
)
144.74
-2.76 (-1.87%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
78
79
Next >
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More
↗
May 29, 2026
This biotechnology firm advances targeted cancer therapies, leveraging genetic insights and strategic partnerships in oncology.
Via
The Motley Fool
Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar)
May 27, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
If You Invested $1000 In Gilead Sciences Stock 15 Years Ago, You Would Have This Much Today
↗
May 26, 2026
Via
Benzinga
Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference
↗
May 24, 2026
Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined several upcoming clinical and regulatory priorities across oncology, inflammation and HIV during a discussion with RBC...
Via
MarketBeat
Gilead Sciences (NASDAQ:GILD) Screens as a Top Dividend Stock with Strong Profitability and Health
↗
May 19, 2026
Via
Chartmill
Gilead Sciences Inc (NASDAQ:GILD) Beats Q1 Estimates But Stock Falls on Hefty Acquisition Costs and Revised Loss Guidance
↗
May 07, 2026
Via
Chartmill
FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
May 22, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
May 22, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
May 21, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio
May 21, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease
May 21, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Compugen Q1 Earnings Call Highlights
↗
May 18, 2026
Compugen (NASDAQ:CGEN) said it remains on track to report interim progression-free survival data in the first quarter of 2027 from its MAIA-ovarian study, as the clinical-stage immuno-oncology company...
Via
MarketBeat
Topics
Earnings
Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation Pipeline
↗
May 17, 2026
Gilead Sciences (NASDAQ:GILD) Chief Commercial Officer and Head of Corporate Affairs Johanna Mercier said the company is leaning on its HIV business while continuing to build out oncology and...
Via
MarketBeat
3 Market-Beating Stocks to Research Further
May 15, 2026
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta y...
Via
StockStory
Gilead Prices $3 Billion of Senior Unsecured Notes
May 14, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference
↗
May 14, 2026
Assembly Biosciences (NASDAQ:ASMB) Chief Medical Officer Anuj Gaggar outlined the company’s virology strategy and upcoming clinical priorities during a Bank of America-hosted discussion, emphasizing...
Via
MarketBeat
Gilead Sciences’s Q1 Earnings Call: Our Top 5 Analyst Questions
May 14, 2026
Gilead Sciences began 2026 with revenue and adjusted earnings per share both exceeding Wall Street expectations, reflecting strong commercial execution and d...
Via
StockStory
Topics
Earnings
Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026
May 13, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead (GILD) Q1 2026 Earnings Call Transcript
↗
May 08, 2026
Gilead (GILD) Q1 2026 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
These S&P500 stocks are moving in today's pre-market session
↗
May 08, 2026
Via
Chartmill
GILD Q1 Deep Dive: HIV Growth, Oncology Pipeline, and Margin Management Shape 2026 Outlook
May 08, 2026
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 4.4% year on year to...
Via
StockStory
What's going on in today's after hours session: S&P500 movers
↗
May 07, 2026
Via
Chartmill
Gilead Sciences’s (NASDAQ:GILD) Q1 CY2026: Beats On Revenue
May 07, 2026
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 4.4% year on year...
Via
StockStory
Gilead Tumbles On Mixed Guidance Update Amid Recent M&A Frenzy
↗
May 07, 2026
Gilead Sciences issued a mixed guidance update late Thursday after the biotech company beat first-quarter sales expectations.
Via
Investor's Business Daily
Gilead Sciences Announces First Quarter Financial Results
May 07, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Likely To Report Higher Q1 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
↗
May 07, 2026
Gilead Sciences (NASDAQ: GILD) will release Q1 earnings on May 7, with analysts expecting $1.91 EPS and $6.92B revenue. Stock closed at $136.30 on April 29.
Via
Benzinga
A Nurix Therapeutics (NRIX) Insider Sold 5,394 Shares for $90,000
↗
May 06, 2026
Nurix Therapeutics, a biotech innovator in targeted cancer therapies, reported a notable insider sale amid strong one-year stock gains.
Via
The Motley Fool
Topics
Regulatory Compliance
Earnings To Watch: Gilead Sciences (GILD) Reports Q1 Results Tomorrow
May 05, 2026
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting earnings this Thursday after market close. Here’s what you need to know. Gilead Sci...
Via
StockStory
Topics
Artificial Intelligence
Tempus AI (TEM) Q1 2026 Earnings Transcript
↗
May 05, 2026
Tempus AI (TEM) Q1 2026 Earnings Transcript
Via
The Motley Fool
Topics
Artificial Intelligence
1 S&P 500 Stock to Own for Decades and 2 We Avoid
May 04, 2026
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec...
Via
StockStory
Topics
Stocks
< Previous
1
2
3
4
5
6
7
8
9
...
78
79
Next >
